Outcome of re-excision for intralesionally treated XXXX .

@entity1 @entity421 @entity5 @entity3
BACKGROUND: The purpose of this study is to evaluate the risk of subsequent local recurrence (LR) and survival of @entity421 ( @entity421 ) @entity1 who underwent re-excision after intralesional excision. METHODS: We analyzed clinical outcomes of 11 @entity421 @entity1 referred after intralesional excision. Average follow-up was 86 months (range: 37-190 months). There were 9 Stage IB lesions and 2 Stage IIB lesions. @entity5 were located in the femur (3) and in other locations (8). Seven @entity1 showing recurrent @entity5 at referral received entire segmental excision while remaining four @entity1 without LR underwent hemi-cortical excision. RESULTS: The 5-year @entity3 free survival rate of 11 @entity1 was 81.8%. @entity1 without evident @entity5 mass did not show further recurrence after re-excision. However, 5 (71.4%) of the 7 @entity1 with recurrent @entity5 relapsed despite segmental re-excision, and their median interval to subsequent LR was 18.8 months (range: 4-9 months). Two of five @entity1 with re-recurrence developed @entity3 which were unresponsive to chemotherapy. CONCLUSIONS: Following inadvertent intralesional procedure, re-excision should be liberally applied before there is an evidence of recurrence. In @entity1 presenting with gross LR, amputation should not be spared unless wide surgical margin can be achieved.
